

Independent Auditors' Report

To The Shareholders of

Beximco Pharmaceuticals Limited

Report on the Financial Statements

We have audited the accompanying financial statements of Beximco Pharmaceuticals Limited, which comprises the Statement of Financial Position as at 30 June 2016, the Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the period from 01 January 2015 to 30 June 2016 (18 months) then ended and a summary of significant accounting policies and other relevant explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards (IFRSs), Bangladesh Financial Reporting Standards (BFRSs), and Bangladesh Accounting Standards (BASs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA) and Bangladesh Standards on Auditing (BSA). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedure that are appropriate in the circumstance, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 30 June 2016, and of its financial performance and its cash flows for the period of 18 months then ended in accordance with International Financial Reporting Standards (IFRSs) and Bangladesh Financial Reporting Standards (BFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Other matter

Financial Statements of the Company for the year ended 31 December 2015 and period ended 30 June 2016 have separately been audited by us. Now the Company is required to follow accounting year as July to June as per Finance Act 2015. For this purpose, separately audited financial statements have been compiled as per directives of The Bangladesh Securities and Exchange Commission (BSEC).

Report on Other Legal and Regulatory Requirements

In accordance with the requirements of the Companies Act 1994 and the Securities and Exchange Rules 1987, we report that:

- (a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- (b) in our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of these books;
- (c) the Statement of Financial Position (Balance Sheet) and Statement of Profit or Loss and other Comprehensive Income (Profit and Loss Account) dealt with by the report are in agreement with the books of account; and
- (d) the expenditure incurred was for the purposes of the company's business.

Dhaka
6 October, 2016



M.J. Abedin & Co.
Chartered Accountants

Beximco Pharmaceuticals Limited
Statement of Financial Position
As at June 30, 2016

		Amount in Taka	
	Notes	June 30, 2016	December 31, 2014
ASSETS			
Non-Current Assets			
Property, Plant and Equipment- Carrying Value	4 (a)	22,235,892,802	20,393,278,737
Intangible Assets	3.3 & 5	380,260,529	235,208,190
Investment in Shares	6 (a)	4,746,834	5,759,927
		8,528,007,810	8,366,279,107
Current Assets			
Inventories	7	2,770,331,675	2,493,657,338
Spares & Supplies	8	614,606,112	554,183,898
Accounts Receivable	9	1,680,606,796	1,397,498,648
Loans, Advances and Deposits	10	1,802,304,185	1,223,673,153
Short Term Investment	11	1,439,037,813	2,475,026,831
Cash and Cash Equivalents	12	221,121,229	222,239,239
		31,148,907,975	29,000,525,961
TOTAL ASSETS			
EQUITY AND LIABILITIES			
Shareholders' Equity			
Issued Share Capital	13	3,862,442,340	3,678,516,520
Share Premium		5,269,474,690	5,269,474,690
Excess of Issue Price over Face Value of GDRs	14	1,689,636,958	1,689,636,958
Capital Reserve on Merger		294,950,950	294,950,950
Revaluation Surplus	4(b)	1,225,100,042	1,299,220,315
Fair Value Gain on Investment		1,295,558	2,308,651
Retained Earnings		10,716,511,871	8,686,077,241
		5,106,928,058	3,372,593,206
Non-Current Liabilities			
Long Term Borrowings-Net off Current Maturity (Secured)	15	2,366,006,599	901,709,327
Liability for Gratuity and WPPF & Welfare Funds	16	984,198,459	741,522,518
Deferred Tax Liability	17	1,756,723,000	1,729,361,361
		2,982,567,508	4,707,747,430
Current Liabilities and Provisions			
Short Term Borrowings (Secured)	18 (a)	1,109,644,270	3,153,121,293
Long Term Borrowings-Current Maturity (Secured)	19	920,388,531	663,838,072
Creditors and Other Payables	20	453,828,612	357,710,839
Accrued Expenses	21	151,086,775	164,283,115
Dividend Payable		385,507	454,720
Income Tax Payable	22	347,233,813	368,339,391
		31,148,907,975	29,000,525,961
TOTAL EQUITY AND LIABILITIES			

The Notes are an integral part of the Financial Statements.


Approved and authorised for issue by the Board of Directors on 6 October, 2016 and signed for and on behalf of the Board :



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Per our report of even date.



M. J. Abedin & Co.
Chartered Accountants

Dhaka
6 October, 2016

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income
For 18 Months Period ended 30th June 2016

Amount in Taka

	Notes	January 2015 - June 2016 (18 Months)	January - June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Net Sales Revenue	23	20,034,502,592	7,068,995,719	12,965,506,873	11,206,885,677
Cost of Goods Sold	24	(10,800,317,358)	(3,835,149,654)	(6,965,167,704)	(6,102,694,323)
Gross Profit		9,234,185,234	3,233,846,065	6,000,339,169	5,104,191,354
Operating Expenses		(4,775,931,931)	(1,626,871,236)	(3,149,060,695)	(2,686,014,518)
Administrative Expenses	27	(689,337,921)	(240,980,804)	(448,357,117)	(398,762,237)
Selling, Marketing and Distribution Expenses	28	(4,086,594,010)	(1,385,890,432)	(2,700,703,578)	(2,287,252,281)
Profit from Operations		4,458,253,303	1,606,974,829	2,851,278,474	2,418,176,836
Other Income	29	412,658,923	100,980,597	311,678,326	521,171,647
Finance Cost	30	(1,030,182,401)	(321,212,167)	(708,970,234)	(724,314,963)
Profit Before Contribution to WPPF & Welfare Funds		3,840,729,825	1,386,743,259	2,453,986,566	2,215,033,520
Contribution to WPPF & Welfare Funds	31	(182,891,896)	(66,035,393)	(116,856,503)	(105,477,787)
Profit Before Tax		3,657,837,929	1,320,707,866	2,337,130,063	2,109,555,733
Income Tax Expenses	32	(709,784,075)	(326,938,528)	(382,845,547)	(581,258,160)
Current Tax		(736,140,227)	(310,173,315)	(425,966,912)	(436,782,844)
Deferred Tax Income / (Expense)		26,356,152	(16,765,213)	43,121,365	(144,475,316)
Profit after Tax for the Period		2,948,053,854	993,769,338	1,954,284,516	1,528,297,573
Other Comprehensive Income - Fair Value Gain / (Loss) on Investment in Listed Shares	6 (c)	(1,013,093)	(661,955)	(351,138)	967,032
Total Comprehensive Income for the Period		2,947,040,761	993,107,383	1,953,933,378	1,529,264,605
Earnings Per Share (EPS) / Adjusted EPS	33	7.63	2.57	5.06	3.96
Number of Shares used to compute EPS		386,244,234	386,244,234	386,244,234	386,244,234

The Notes are an integral part of the Financial Statements.


Approved and authorised for issue by the Board of Directors on 6 October, 2016 and signed for and on behalf of the Board :



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Per our report of even date.

Dhaka
6 October, 2016



M. J. Abedin & Co.
Chartered Accountants

Beximco Pharmaceuticals Limited

Statement of Changes in Equity

For 18 Months Period ended January 1, 2015 - June 30, 2016

Amount in Taka

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Fair Value Gain on Investment	Retained Earnings	Total
Balance as on January 01, 2015	3,678,516,520	5,269,474,690	1,689,636,958	294,950,950	1,299,220,315	2,308,651	8,686,077,241	20,920,185,325
Total Comprehensive Income for the period :								
Profit for the Period	-	-	-	-	-	-	2,948,053,854	2,948,053,854
Other Comprehensive Income/(Loss)	-	-	-	-	-	(1,013,093)	-	(1,013,093)
Transactions with the Shareholders:								
Cash Dividend- 2014 & 2015 (Interim)	-	-	-	-	-	-	(754,095,886)	(754,095,886)
Stock Dividend for 2014	183,925,820	-	-	-	-	-	(183,925,820)	-
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(20,402,482)	-	20,402,482	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(53,717,791)	-	-	(53,717,791)
Balance as on June 30, 2016	3,862,442,340	5,269,474,690	1,689,636,958	294,950,950	1,225,100,042	1,295,558	10,716,511,871	23,059,412,409
Number of Shares								386,244,234
Net Asset Value (NAV) Per Share								59.70

For the Year ended January - December 2014

Balance as on January 01, 2014	3,503,349,070	5,269,474,690	1,689,636,958	294,950,950	1,349,578,805	1,341,619	7,667,220,373	19,775,552,465
Total Comprehensive Income for the period :								
Profit for the year	-	-	-	-	-	-	1,528,297,573	1,528,297,573
Other Comprehensive Income	-	-	-	-	-	967,032	-	967,032
Transactions with the Shareholders:								
Cash Dividend for 2013	-	-	-	-	-	-	(350,334,907)	(350,334,907)
Stock Dividend for 2013	175,167,450	-	-	-	-	-	(175,167,450)	-
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(16,061,652)	-	16,061,652	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(34,296,838)	-	-	(34,296,838)
Balance as on December 31, 2014	3,678,516,520	5,269,474,690	1,689,636,958	294,950,950	1,299,220,315	2,308,651	8,686,077,241	20,920,185,325
Number of Shares								367,851,652
Net Asset Value (NAV) Per Share								56.87

The Notes are an integral part of the Financial Statements.


Approved and authorised for issue by the Board of Directors on 6 October, 2016 and signed for and on behalf of the Board :



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Per our report of even date.



M. J. Abedin & Co.
Chartered Accountants

Dhaka
6 October, 2016

Beximco Pharmaceuticals Limited
Statement of Cash Flows
For 18 Months Period ended 30th June 2016

	Amount in Taka	
	January 2015 - June 2016 (18 Months)	January - December 2014 (12 Months)
Cash Flows from Operating Activities :		
Receipts from Customers and Others	19,756,621,890	11,085,037,894
Payments to Suppliers and Employees	(15,204,763,705)	(8,240,584,352)
Cash Generated from Operations	4,551,858,185	2,844,453,542
Interest Paid	(1,030,182,401)	(724,314,963)
Interest Received	404,847,333	489,970,647
Income Tax Paid	(757,245,805)	(394,128,824)
Net Cash Generated from Operating Activities	3,169,277,312	2,215,980,402
Cash Flows from Investing Activities :		
Acquisition of Property, Plant and Equipment	(2,975,250,144)	(2,778,797,453)
Intangible Assets	(165,351,713)	(56,321,506)
Disposal of Property, Plant and Equipment	9,583,953	7,615,792
Dividend Received	1,427,955	1,427,955
Decrease in Short Term Investment	1,035,989,018	551,356,330
Net Cash Used in Investing Activities	(2,093,600,931)	(2,274,718,882)
Cash Flows from Financing Activities :		
Net Increase/(Decrease) in Long Term Borrowings- Note 18 (c)	55,519,429	(340,756,861)
Net Increase/(Decrease) in Short Term Borrowings- Note 18 (c)	(378,148,721)	376,855,168
Dividend Paid	(754,165,099)	(350,853,554)
Net Cash Generated from Financing Activities	(1,076,794,391)	(314,755,247)
Increase/(Decrease) in Cash and Cash Equivalents	(1,118,010)	(373,493,727)
Cash and Cash Equivalents at Beginning of Period	222,239,239	595,732,966
Cash and Cash Equivalents at End of Period	221,121,229	222,239,239
Net Operating Cash Flow Per Share	8.21	6.02
Number of Shares used to compute Net Operating Cash Flow Per Share	386,244,234	367,851,652

The Notes are an integral part of the Financial Statements.


Approved and authorised for issue by the Board of Directors on 6 October, 2016 and signed for and on behalf of the Board :



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Per our report of even date.



M. J. Abedin & Co.
Chartered Accountants

Dhaka
6 October, 2016

Beximco Pharmaceuticals Limited
Notes to the Financial Statements
 As at and for the period ended 30 June 2016

1. Reporting entity

1.1 About the company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company of the Beximco Group engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka.

1.2 Nature of Business

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products including life saving intravenous fluids, Therapeutic Nutrition Products and Active Pharmaceutical Ingredients (APIs). Products of the company are sold in domestic and international markets. The company also provides contract manufacturing services.

2. Basis of Preparation of Financial Statements

2.1 Basis of Measurement

The financial statements have been prepared on Historical Cost Basis except land, building and plant & machinery being revalued on 31 December 2008, investment in shares of listed company being valued at year end quoted price and the cash flow statement being prepared on cash basis.

2.2 Statement of Compliance

The financial statements have been prepared in compliance with the requirements of the Companies Act, 1994, the Securities & Exchange Rules 1987, the Listing Regulations of Dhaka and Chittagong Stock Exchanges and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs), and Bangladesh Financial Reporting Standards (BFRSs).

2.3 Presentation of Financial Statements

The presentation of the financial statements is in accordance with the guidelines provided by IAS 1: Presentation of Financial Statements.

The financial statements comprises of:

- (a) a Statement of Financial Position as at the end of the period ended 30 June 2016 ;
- (b) a Statement of Profit or Loss and Other Comprehensive Income for the period 01 January 2015 to 30 June 2016 (18 months);
- (c) a Statement of Changes in Equity for the period 01 January 2015 to 30 June 2016 (18 months);
- (d) a Statement of Cash Flows for the period 01 January 2015 to 30 June 2016 (18 months); and
- (e) notes, comprising summary of significant accounting policies and explanatory information.

2.4 Reporting Period & Comparative Information

The financial statements have been prepared for 18 (eighteen) months (from 1st January 2015 to 30th June 2016) as per directive of Bangladesh Securities and Exchange Commission (BSEC) to facilitate the adoption of reporting period of July to June in place of existing reporting period of calendar year (January to December) in compliance to the requirement of the National Board of Revenue (NBR) to follow uniform financial year.

Therefore, the financial statements for the period of 18 months (01.01.2015 to 30.06.2016) are not entirely comparable with the comparative of 12 months (01.01.2014 to 31.12.2014).

2.5 Authorisation for issue

The financial statements have been authorised for issue by the Board of Directors 6 October, 2016.

2.6 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.7 Use of Estimates and Judgments

The preparation of financial statements in conformity with the IFRSs including IASs require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, accrued expenses, others payable and deferred liability for gratuity.

3. Significant Accounting Policies

The accounting principles and policies in respect of material items of financial statements set out below have been applied consistently to all periods presented in these financial statements.

3.1 Revenue Recognition

In compliance with the requirements of IAS 18: Revenue, revenue receipts from customers against sales is recognized when products are dispatched to customers, that is, when the significant risk and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods.

Revenue from sales is exclusive of VAT.

Cash dividend income on investment in shares is recognized on approval of said dividend in the annual general meeting. Stock dividend income (Bonus Shares) is not considered as revenue.

3.2 Property, Plant and Equipment**3.2.1 Recognition and Measurement**

This has been stated at cost or revalued amount less accumulated depreciation in compliance with the requirements of IAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

3.2.2 Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

3.2.3 Depreciation

Depreciation is provided to amortise the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment. Depreciation is provided at the following rates on reducing balance basis:

Building and Other Construction	2 %- 10%
Plant and Machinery	5% -15%
Furniture & Fixtures	10%
Transport & Vehicle	20%
Office Equipment	10% -15%

3.2.4 Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the income statement, which is determined with reference to the net book value of the assets and net sales proceeds.

3.3 Intangible Assets

Intangible assets are stated at cost less provisions for amortization and impairments. Licenses, patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring and developing computer software for internal use and internet sites for external use are capitalized as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset. Also, the research and development expenditures that are definite to yield benefit to the company are capitalized.

3.4 Leased Assets

In compliance with the IAS 17: Leases, cost of assets acquired under finance lease along with related obligation has been accounted for as assets and liabilities respectively of the company, and the interest element has been charged as expenses. Lease payments made under finance leases are apportioned between the finance expenses and the reduction of the outstanding liability.

3.5 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

3.5.1 Financial assets

Financial assets of the company include cash and cash equivalents, accounts receivable and other receivables. The company initially recognizes receivable on the date they are originated. All others financial assets are recognized initially on the date at which the company becomes a party to the contractual provisions of the transaction. The company derecognizes a financial asset when, and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and rewards of ownership of the financial asset are transferred.

3.5.1(a) Accounts Receivable

Accounts receivable are created at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, taking into account aging, previous experience and general economic conditions. When an accounts receivable is determined to be uncollected it is written off, firstly against any provision available and then to the profit and loss account. Subsequent recoveries of amounts previously provided for are credited to the profit and loss account.

3.5.1(b) Cash and Cash Equivalents

Cash and cash equivalents include cash in hand, in transit and with banks on current and deposit accounts which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

3.5.1(c) Investment in Shares

Investment in shares of listed company is valued at a price quoted in the stock exchange at year end. Investment in other shares is valued at cost.

3.5.2 Financial Liability

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire.

Finance liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.6 Impairment**(a) Financial Assets**

Accounts receivable and other receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effects on the estimated future cash flows of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy etc.

(b) Non-Financial Assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impairment loss if, and only if, the recoverable amount of the asset is less than its carrying amount. Impairment loss is recognized immediately in profit or loss, unless the asset is carried at revalued amount. Any impairment loss of a revalued asset shall be treated as a revaluation decrease.

3.7 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

3.8 Provisions

A provision is recognized in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the date of statement of financial position. Where the effect of time value of money is material, the amount of provision is measured at the present value of the expenditures expected to be required to settle the obligation.

3.9 Income Tax Expense

Income tax expense comprises of current and deferred tax. Income tax expense is recognized in the Statement of Comprehensive Income and accounted for in accordance with the requirements of IAS 12: Income Tax.

Current Tax

Current tax is the expected tax payable on the taxable income for the period, and any adjustment to tax payable in respect of previous years. The company qualifies as a "Publicly Traded Company"; hence the applicable Tax Rate is 25%.

Deferred Tax

The company has recognized deferred tax using balance sheet method in compliance with the provisions of IAS 12: Income Taxes. The company's policy of recognition of deferred tax assets/ liabilities is based on temporary differences (Taxable or deductible) between the carrying amount (Book value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income/expenses has been considered to determine net profit after tax and earnings per shares (EPS).

A deferred tax asset is recognized to the extent that it is probable that future taxable profit will be available, against which temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realized.

3.10 Interest Income

Interest income is recognized on accrual basis.

3.11 Borrowing Cost

Borrowing costs are recognized as expenses in the period in which they are incurred unless capitalization of such is allowed under IAS 23: Borrowing Costs.

3.12 Employee Benefits

The company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: Employee Benefits.

The cost of employee benefits is charged off as revenue expenditure in the period to which the contributions relate.

The company's employee benefits include the following:

(a) Defined Contribution Plan (Provident Fund)

The company has a registered provident fund scheme (Defined Contribution Plan) for employees of the company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable trust. All permanent employees contribute 10% of their basic salary to the provident fund and the company also makes equal contribution.

The company recognizes contribution to defined contribution plan as an expense when an employee has rendered services in exchange for such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

(b) Defined Benefit Plan (Gratuity)

This represents unfunded gratuity scheme for its permanent employees. Employees are entitled to gratuity benefit after completion of minimum five years of service in the company.

Though no valuation was done to quantify actuarial liabilities as per the IAS 19: Employee Benefits, such valuation is not likely to yield a result significantly different from the current provision.

(c) Short-term employee benefits

Short-term employee benefits include salaries, bonuses, leave encashment, etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

(d) Contribution to Workers' Profit Participation and Welfare Funds

This represents 5% of net profit before tax contributed by the company as per provisions of the Bangladesh Labor (amendment) Act 2013 and is payable to workers as defined in the said law.

(e) Insurance Scheme

Employees of the company are covered under insurance schemes.

3.13 Share Premium

The Share Premium shall be utilized in accordance with the provisions of the Companies Act, 1994 and as per direction of the Securities and Exchange Commission in this respect.

3.14 Proposed Dividend

The amount of proposed dividend is not accounted for but disclosed in the notes to the accounts in accordance with the requirements of the International Accounting Standard (IAS) 1: Presentation of Financial Statements. Also the proposed dividend is not considered as liability in accordance with the requirement of International Accounting Standard (IAS) 10: Events After The Reporting Period, because no obligation exists at the time of approval of accounts and recommendation of dividend by the board of Directors. The Board of Directors in its meeting held on 20 April 2016 while considering the audited accounts for the year ended on 31st December 2015 recommended 10% cash and 5% stock dividend subject to approval of the shareholders in the Annual General Meeting scheduled on 4 June 2016. Subsequent to that, the Bangladesh Securities and Exchange Commission issued directive to hold Annual General Meeting with 18 months Accounts for first time adoption of the changes in the Accounting Year as required by the Finance Act 2015. Accordingly the Annual General Meeting of the Company was deferred and the cash dividend proposed was paid to the shareholders as Interim Dividend. Therefore, the 10% cash dividend which was already paid has been accounted for in the accounts being reported. The 5% stock dividend and 5% final cash dividend as recommended by the board in its meeting held on October 6, 2016 while approving the 18 months audited accounts for the period ended on June 30, 2016 has not been accounted for as per policy.

3.15 Earnings per Share (EPS)

This has been calculated in compliance with the requirements of IAS 33: Earnings Per Share by dividing the basic earnings by the weighted average number of ordinary shares outstanding during the period.

Current Period (January 2015 to June 2016)

The Bonus Shares issued during the year 2014 were treated as if they always had been in issue. Hence, in computing the Basic EPS of Current Period (January 2015 to June 2016), the total number of shares including the said bonus shares has been considered as the Weighted Average Number of Shares outstanding during the Current Period (January 2015 to June 2016).

Earlier Year (2014)

The number of shares outstanding before the bonus issue has been adjusted for the proportionate change in the number of shares outstanding as if the bonus issue had occurred at the beginning of the earliest period reported (2014), and accordingly, in calculating the adjusted EPS of 2014, the total number of shares including the subsequent bonus issued in 2015 has been considered as the Weighted Average number of Shares outstanding during the year 2014.

The basis of computation of number of shares as stated above is in line with the provisions of IAS 33: Earning per Share. The logic behind this basis, as stated in the said IAS is that the bonus Shares are issued to the existing shareholders without any consideration, and therefore, the number of shares outstanding is increased without an increase in resources.

Diluted Earnings per Share

No diluted EPS is required to be calculated for the period as there was no scope for dilution during the period under review.

3.16 Foreign Currency Transactions

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date.

The monetary assets and liabilities, if any, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchanges ruling at that date. Exchange differences are charged off as revenue expenditure in compliance with the provisions of IAS 21: The Effects of Changes in Foreign Exchange Rates.

3.17 Statement of Cash Flows

The Statement of Cash Flow has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generated from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS 7, whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

3.18 Events after Reporting Period

Events after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

4 (a) Property, Plant and Equipment

As on June 30, 2016

Amount in Taka

Particulars	Land	Building and Other Constructions	Plant and Machinery	Furniture and Fixtures	Transport and Vehicle	Office Equipment	Total
Cost							
At January 01, 2015	3,343,741,442	6,410,090,320	10,573,115,701	197,001,369	596,845,504	390,013,667	21,510,808,003
Additions- January 2015 to June 2016	-	154,933,066	499,981,926	37,334,604	107,098,489	118,553,280	917,901,365
Transferred in & Capitalized	-	147,151,810	257,977,765	254,013	-	3,298,860	408,682,448
Disposal during the period	-	-	(7,057,699)	(16,946,545)	(3,931,886)	(9,716,371)	(37,652,501)
Cost at June 30, 2016	3,343,741,442	6,712,175,196	11,324,017,693	217,643,441	700,012,107	502,149,436	22,799,739,315
Accumulated Depreciation							
At January 01, 2015	-	1,216,063,103	3,582,516,866	79,383,211	292,067,629	255,418,950	5,425,449,759
Depreciation Charged- January 2015 to June 2016	-	241,207,131	735,361,153	18,344,246	92,584,435	36,711,350	1,124,208,315
Adjustment for Assets disposed off	-	-	(6,520,549)	(11,988,652)	(2,531,542)	(8,183,994)	(29,224,737)
Accumulated Depreciation at June 30, 2016	-	1,457,270,234	4,311,357,470	85,738,805	382,120,522	283,946,306	6,520,433,337
Net Book Value June 30, 2016	3,343,741,442	5,254,904,962	7,012,660,223	131,904,636	317,891,585	218,203,130	16,279,305,978
Capital Work in Progress							5,956,586,824
Carrying Value as on June 30, 2016							22,235,892,802

Assets include leasehold assets of Tk. 1,277,737,554 at cost and Tk.1,053,077,850 at carrying value.

As on December 31, 2014

Particulars	Land	Building and Other Constructions	Plant and Machinery	Furniture and Fixtures	Transport and Vehicle	Office Equipment	Total
Cost							
At January 01, 2014	3,302,882,482	6,370,758,420	10,034,644,242	173,333,992	548,077,240	358,363,316	20,788,059,692
Addition During the Year	40,858,960	39,331,900	111,420,014	24,240,377	59,392,132	31,650,351	306,893,734
Transferred in & Capitalized	-	-	427,051,445	-	-	-	427,051,445
Disposal during the year	-	-	-	(573,000)	(10,623,868)	-	(11,196,868)
As on 31 December 2014	3,343,741,442	6,410,090,320	10,573,115,701	197,001,369	596,845,504	390,013,667	21,510,808,003
Accumulated Depreciation							
At January 01, 2014	-	1,052,546,636	3,090,128,096	69,430,902	237,436,147	237,273,060	4,686,814,841
Depreciation for the year	-	163,516,467	492,388,770	10,375,309	61,346,435	18,145,890	745,772,871
Adjustment for Assets disposed off	-	-	-	(423,000)	(6,714,953)	-	(7,137,953)
As on 31 December, 2014	-	1,216,063,103	3,582,516,866	79,383,211	292,067,629	255,418,950	5,425,449,759
Net Book Value December 31, 2014	3,343,741,442	5,194,027,217	6,990,598,835	117,618,158	304,777,875	134,594,717	16,085,358,244
Capital Work in Progress							4,307,920,493
Carrying Value as on December 31, 2014							20,393,278,737

Capital Work in Progress is arrived at as follows :

	Amount in Taka	
	30 June, 2016	31 December, 2014
Opening Balance at beginning of the period	4,307,920,493	2,263,068,219
Addition- January 2015 to June 2016	2,057,348,779	2,471,903,719
	6,365,269,272	4,734,971,938
Transferred & Capitalized	(408,682,448)	(427,051,445)
Building and Other Constructions	(147,151,810)	-
Plant & Machinery	(257,977,765)	(427,051,445)
Furniture & Fixture	(254,013)	-
Office Equipment	(3,298,860)	-
Closing balance at end of period	<u>5,956,586,824</u>	<u>4,307,920,493</u>

4 (b). Revaluation Surplus

S.F. Ahmed & Co, Chartered Accountants and Valuers revalued the land, building and plant & machinery of the Company as of 31 December 2008, following "Current cost method". Such revaluation resulted into a revaluation surplus aggregating Tk. 1,711,174,747. Current balance is arrived at as follows:

Opening Balance at beginning of the period	1,299,220,315	1,349,578,805
Adjustment for depreciation on revalued assets	(20,402,482)	(16,061,652)
Adjustment for Deferred Tax on revalued assets	(53,717,791)	(34,296,838)
	<u>1,225,100,042</u>	<u>1,299,220,315</u>

5. Intangible Assets

This consists of as follows

	Balance 01.01.2015	Addition (Jan 2015 - Jun 2016)	Amortized (Jan 2015 - Jun 2016)	Balance June 30, 2016
Product development, Licensing and Marketing Rights	230,551,508	74,789,570	(16,713,018)	288,628,060
ERP Project	-	90,562,143	-	90,562,143
Other Software	4,656,682	-	(3,586,356)	1,070,326
	235,208,190	165,351,713	(20,299,374)	380,260,529

6. Investment in Shares

	30 June, 2016	31 December, 2014
(a) Investment Details:		
(i) Bangladesh Export Import Co. Ltd.	3,177,384	4,190,477
(ii) Central Depository Bangladesh Ltd. (CDBL)	1,569,450	1,569,450
	<u>4,746,834</u>	<u>5,759,927</u>

This is arrived at as follows:

	Bangladesh Export Import Co. Ltd.	Central Depository Bangladesh Ltd.
Investment as on January 01, 2015	4,190,477	1,569,450
Fair value gain/(Loss) on investment	(1,013,093)	-
Investment as on June 30, 2016	<u>Tk. 3,177,384</u>	<u>1,569,450</u>

(b) Number of Shares:

As on January 01, 2015	115,123	571,182
Stock Dividend for 2014	17,268	-
As on June 30, 2016	<u>132,391</u>	<u>571,182</u>

(c) Fair Value Gain/(Loss) on Investment

Fair market value of 132,391 shares of Bangladesh Export Import Co. Ltd.	3,177,384
Less Investment at beginning of the period	<u>4,190,477</u>
Fair Value Gain / (Loss)	<u>(1,013,093)</u>

(d) The shares of Bangladesh Export Import Co. Ltd. are listed in Dhaka and Chittagong Stock Exchanges. The market value of each share of Bangladesh Export Import Co. Ltd. on last working day of the period was Tk. 24.00 in Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. Shares of CDBL are not traded.

7. Inventories

Amount in Taka

This consists of as follows :	30 June, 2016	31 December, 2014
Finished Goods	639,923,877	633,692,189
Work in Process	194,155,965	171,815,679
Raw Materials	792,484,516	637,080,994
Packing Materials	459,631,224	424,461,374
Laboratory Chemicals	338,991	550,984
Physician Samples	127,674,561	149,875,483
Materials in Transit	<u>556,122,541</u>	<u>476,180,635</u>
	<u>2,770,331,675</u>	<u>2,493,657,338</u>

8. Spares & Supplies

This consists of as follows :

Spares & Accessories	495,625,730	399,537,644
Stock of Stationery	11,624,684	11,284,736
Literature & Promotional Materials	<u>107,355,698</u>	<u>143,361,518</u>
	<u>614,606,112</u>	<u>554,183,898</u>

9. Accounts Receivable

This includes receivable of Tk. 107,075,699 equivalent to US\$ 1,372,765 as on 30 June 2016 (on 31-12-2014 Tk. 136,834,694 equivalent to US \$ 1,763,334) against export sales.

This also includes Tk. 1,430,821,670 due from I & I Services Ltd., who provides distribution service to the Company and a "Related Party". The maximum amount due from that company during the period was Tk. 1,430,821,670 on 30 June, 2016.

The receivables on account of Export sales are fully secured against Letter of Credit while the others are unsecured but considered good.

No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person.

10. Loans, Advances and Deposits

This is unsecured, considered good and consists of as follows :

	Amount in Taka	
	30 June, 2016	31 December, 2014
Clearing & Forwarding	83,654,786	54,354,123
VAT	273,720,987	217,516,529
Claims Receivable	20,242,657	14,620,213
Security Deposit & Earnest Money	26,407,411	27,652,694
Lease Deposit	28,691,017	21,812,942
Capital Expenditure/ Project Expenses	97,081,087	50,029,753
Bank Guarantee Margin	198,889,697	132,711,063
Advance against Salary	2,951,066	1,257,096
Rent Advance	88,981,864	55,699,183
Motor Cycle	19,535,002	9,716,674
Raw & Packing Material	157,814,961	124,010,046
Prepaid Expenses	395,386,302	422,209,729
Overseas Liaison Office	322,417,705	21,116,922
Others	19,067,068	15,032,617
	<u>67,462,575</u>	<u>55,933,569</u>
	<u>1,802,304,185</u>	<u>1,223,673,153</u>

(a) The maximum amount due from the employees during the period was Tk. 89,024,168 on 31 May, 2016.

(b) No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person, except as stated above.

(c) No amount was due from any related party.

(d) Prepaid expense includes Tk. 302,987,514 for Insurance premium paid to German Export Credit Agency Euler Hermes Aktiengesellschaft, Hamburg for guarantee Insurance premium which is an integral part of the overseas loan financing agreement with BHF-Bank Aktiengesellschaft, Frankfurt, Germany. Part of the premium related to the period of construction of the project shall be capitalized while the rest shall be charged to expenses over the tenure of the loan.

11. Short Term Investment

This represents the Company's temporary investment with Bangladesh Export Import Company Limited, carrying interest 1% above bank interest rate. This investment is returnable as and when required by the Company.

12. Cash and Cash Equivalents

This consists of as follows :

	Amount in Taka	
	30 June, 2016	31 December, 2014
(a) Cash in Hand (including Imprest Cash)	2,812,238	3,218,618
(b) Cash at Bank :		
(i) Current & FC Account	186,824,492	190,573,819
(ii) FDR Account	31,484,499	28,446,802
	<u>221,121,229</u>	<u>222,239,239</u>

13. Issued Share Capital

This represents :

Amount in Taka

	30 June, 2016	31 December, 2014
A. Authorized :		
500,000,000 Ordinary Shares of Tk. 10/- each	5,000,000,000	5,000,000,000
41,000,000 Fully Convertible, 5% Dividend, Preference Shares of Tk. 100/- each	4,100,000,000	4,100,000,000
	<u>9,100,000,000</u>	<u>9,100,000,000</u>
B. Issued, Subscribed and Paid-up :		
51,775,750 shares of Tk. 10/- each fully paid-up in cash	517,757,500	517,757,500
297,226,087 Bonus Shares (2014: 278,833,505) of Tk. 10/- each	2,972,260,870	2,788,335,050
5,951,250 Shares of Tk. 10/- each issued in Exchange of Shares of Beximco Infusions Ltd.	59,512,500	59,512,500
31,291,147 Shares issued on conversion of Preference Shares	312,911,470	312,911,470
	<u>3,862,442,340</u>	<u>3,678,516,520</u>

The movement of Ordinary Shares during the Period ended June 30, 2016 is as follows :

	Number of Shares	Amount in Taka
Balance as on January 01, 2015	367,851,652	3,678,516,520
Bonus Shares issued during the period (for 2014)	18,392,582	183,925,820
Balance as on June 30, 2016	<u>386,244,234</u>	<u>3,862,442,340</u>

C. Composition of Shareholding of Ordinary Shares:

	30 June, 2016		31 December, 2014	
	No. of shares	% of Share Capital	No. of shares	% of Share Capital
Sponsors:				
A S F Rahman	7,843,194	2.03	7,469,709	2.03
Salman F Rahman	7,861,555	2.04	7,487,196	2.04
Associates and Other Directors	35,218,844	9.12	33,414,339	9.08
Foreign Investors	140,338,026	36.33	93,038,941	25.29
ICB & Other Investors Account	62,590,222	16.20	55,940,961	15.21
General Public & Institutions	132,392,393	34.28	170,500,506	46.35
	<u>386,244,234</u>	<u>100</u>	<u>367,851,652</u>	<u>100</u>

D. Distribution Schedule of Ordinary Shares:

Range of Holdings In number of shares	No. of Shareholders		% of Shareholders		Number of Shares		% of Share Capital	
	30 June, 2016	31 Dec, 2014	30 June, 2016	31 Dec, 2014	30 June, 2016	31 Dec, 2014	30 June, 2016	31 Dec, 2014
1 to 499	50,793	65,544	75.05%	72.90%	6,768,689	8,240,906	1.75%	2.24%
500 to 5,000	14,375	20,786	21.24%	23.12%	20,930,046	30,918,582	5.42%	8.41%
5,001 to 10,000	1,184	1,753	1.75%	1.95%	8,441,882	12,555,227	2.19%	3.41%
10,001 to 20,000	613	930	0.91%	1.03%	8,685,273	13,111,006	2.25%	3.56%
20,001 to 30,000	201	281	0.30%	0.31%	5,007,247	6,909,593	1.30%	1.88%
30,001 to 40,000	86	128	0.13%	0.14%	3,010,665	4,498,146	0.78%	1.22%
40,001 to 50,000	82	102	0.12%	0.11%	3,756,886	4,660,402	0.97%	1.27%
50,001 to 100,000	150	165	0.22%	0.19%	10,505,997	12,172,549	2.72%	3.31%
100,001 to 1,000,000	167	191	0.25%	0.21%	47,746,257	50,601,331	12.36%	13.76%
Over 1,000,000	28	33	0.04%	0.04%	271,391,292	224,183,910	70.26%	60.94%
Total	67,679	89,913	100%	100%	386,244,234	367,851,652	100%	100%

E. Market Price of Ordinary Shares :

The shares are listed with Dhaka, Chittagong and AIM of London Stock Exchanges. On 30.06.2016 each share was quoted at Tk. 83.50 (on 31.12.2014 Tk. 58.70) in Dhaka Stock Exchange Ltd.; Tk. 83.00 (on 31.12.2014 Tk. 59.10) in Chittagong Stock Exchange Ltd.; and GBP 0.2937 in London Stock Exchange (on 31.12.2014 GBP 0.1800).

F. Option on unissued Ordinary Shares :

There was no option on unissued shares as on 30.06.2016.

14. Excess of Issue Price over Face Value of GDRs

This represents the issue price of 28,175,750 GDRs at Tk. 2,244,080,670 net off face value of underlying shares against GDRs and GDR issue expenses.

15. Long Term Borrowings - Net off Current Maturity (Secured)

This arrived at as follows :

	Amount in Taka	
	30 June, 2016	31 December, 2014
(a) Project Loan - Local Banks	-	608,901,223
(b) Project Loan - BHF Bank, Germany	469,408,422	-
(c) Obligation Under Finance Leases	412,250,396	292,808,104
(d) AB Bank	1,484,347,781	-
	<u>2,366,006,599</u>	<u>901,709,327</u>

(a) Project Loan - Local Banks

This loan was sanctioned under the consortium arrangement of Janata Bank Ltd., Sonali Bank Ltd., Agrani Bank Ltd., Rupali Bank Ltd. and United Commercial Bank Ltd. for the US FDA standard oral solid dosage facility of the company. Janata Bank is the lead bank to the consortium.

This Loan is secured against :

- (i) First (registered mortgage) charge on paripassu basis with the participating banks on 1,113 decimals of land at Kathaldia, Aushpara, Tongi of Gazipur along with the building and other constructions thereon; and
- (ii) First paripassu charge by way of hypothecation on all assets of the company excepting the machineries and equipments financed / to be financed by BHF Bank, Germany.
- (iii) This Loan, carrying interest at 11.5% to 13% per annum, is repayable in quarterly installments ending by 2017.

(b) Project Loan - BHF Bank, Germany

This represents part of the foreign currency loan of US \$ 51.559 million sanctioned by BHF-Bank Aktiengesellschaft, Frankfurt, Germany to partially finance the machinery and equipment to be procured for expansion and diversification project being implemented by the company.

The loan has exclusive first charge by way of hypothecation against the machinery and equipment being procured under the finance. The loan carries interest @ 6 month's USD LIBOR plus 2.25% per annum. The lender will receive commitment fee @ 0.50% on the undisbursed portion of the loan.

(c) Obligation Under Finance Leases

Amount in Taka

	30 June, 2016	31 December, 2014
Gross Finance Lease - minimum lease Liability:		
Within one year	242,977,536	186,760,624
After one year	513,274,630	429,486,607
Total	756,252,166	616,247,231
Less future finance charges on finance lease liability	(186,621,695)	(195,948,111)
Present Value of Finance Lease liability	<u>569,630,471</u>	<u>420,299,120</u>
This consists of as follows:		
Within one year	157,380,075	127,491,016
Within two to five years	412,250,396	292,808,104
Total Present Value of Finance Lease liability	<u>569,630,471</u>	<u>420,299,120</u>

16. Liability for Gratuity and WPPF & Welfare Funds

Liability for gratuity is the amount payable to the permanent employees at the time of separation from the company. The liability for WPPF refers to the undistributed portion of Workers' Profit Participation and Welfare Fund lying with the company.

	Amount in Taka	
	30 June, 2016	31 December, 2014
(a) Gratuity Payable		
Opening Balance at beginning of the period	337,652,786	284,163,669
Provisions during the period	128,134,755	66,915,861
	465,787,541	351,079,530
Paid during the period	(20,560,620)	(13,426,744)
Closing balance at end of period	<u>445,226,921</u>	<u>337,652,786</u>
 (b) Workers Profit Participation and Welfare Fund	 <u>538,971,538</u>	 <u>403,869,732</u>
	<u>984,198,459</u>	<u>741,522,518</u>

17. Deferred Tax Liability

This arrived at as follows :

Opening Balance at beginning of the period	1,729,361,361	1,550,589,207
Addition during the period:		
Deferred Tax on Assets (cost basis)-Note : 32	(26,356,152)	144,475,316
Deferred Tax on revalued amount	53,717,791	34,296,838
Closing balance at end of period	<u>1,756,723,000</u>	<u>1,729,361,361</u>

18. (a) Short Term Borrowings (Secured)

This consists of :

	Amount in Taka	
	30 June, 2016	31 December, 2014
Janata Bank Ltd. - Cash Credit-Hypothecation Loan	1,109,644,270	1,487,792,991
AB Bank, Principal Branch	-	1,665,328,302
	<u>1,109,644,270</u>	<u>3,153,121,293</u>

(b) Short Term Borrowings from AB Bank, Principal Branch as mentioned above, has subsequently been converted as Long Term loan payable in 18 quarterly installments commencing from September 2016.

(c) Conversion of Short term loan into long term being a non-cash event, the net Increase/ Decrease in the Short/Long Term borrowings as reported in the cash flow statement does not include such conversion.

19. Long Term Borrowings-Current Maturity (Secured)

This consists of as follows and is payable within next twelve months from the Balance Sheet date :

(a) Project Loan - Local Banks	444,621,118	536,347,056
(b) Project Loan - BHF Bank, Germany	41,054,236	-
(c) Obligation Under Finance Leases	157,380,075	127,491,016
(d) AB Bank	<u>277,333,102</u>	<u>-</u>
	<u>920,388,531</u>	<u>663,838,072</u>

20. Creditors and Other Payables

This consists of :

Goods & Services	144,676,791	202,020,182
Provident Fund	248,809,046	124,323,489
Advance Against Export	9,097,700	3,618,784
Others	<u>51,245,075</u>	<u>27,748,384</u>
	<u>453,828,612</u>	<u>357,710,839</u>

21. Accrued Expenses

This is unsecured, falling due within one year and consists of as follows :

For Expenses	85,051,382	60,155,328
Workers' Profit Participation and Welfare Funds - current period expense	<u>66,035,393</u>	<u>104,127,787</u>
	<u>151,086,775</u>	<u>164,283,115</u>

22. Income Tax Payable

This is arrived at as follows :

Opening Balance	368,339,391	325,685,371
Provision for the period	766,053,375	421,487,672
Short/(Excess) Provision for previous years	(29,913,148)	15,295,172
	<u>1,104,479,618</u>	<u>762,468,215</u>
AIT & Treasury deposits during the period	<u>(757,245,805)</u>	<u>(394,128,824)</u>
	<u>347,233,813</u>	<u>368,339,391</u>

23. Net Sales Revenue

This consists of as follows :

	Amount in Taka			
	January 2015- June 2016 (18 Months)	January-June 2016 (6 Months)	January - Dec 2015 (12 Months)	January - Dec 2014 (12 Months)
Local Sales	18,806,149,764	6,682,982,389	12,123,167,375	10,706,417,075
Export*	1,228,352,828	386,013,330	842,339,498	500,468,602
	<u>20,034,502,592</u>	<u>7,068,995,719</u>	<u>12,965,506,873</u>	<u>11,206,885,677</u>
*Export equivalent US\$	\$15,809,891	\$4,948,889	\$10,861,002	\$6,473,721

Sales represents:

Product Category	Unit	Quantity			
		January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Tablet, Capsule, Suppository & DPI	Million pcs.	5,308.62	1,913.93	3,394.69	2,998.47
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable and Inhaler	Million pcs.	121.46	45.80	75.66	70.72
Diet Care Products	Pcs	16,069	10,157	5,912	-
Active Pharmaceutical Ingredients	Kg	282,789	113,953	168,836	177,354
Liquid Nitrogen	Liter	725,260	241,505	483,755	475,012

24. Cost of Goods Sold

This is made-up as follows :

	Amount in Taka			
	January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Work-in-Process (Opening)	171,815,679	156,136,258	171,815,679	204,755,943
Materials Consumed (Note: 25)	8,002,141,393	2,822,057,040	5,180,084,353	4,498,531,078
Factory Overhead (Note: 26)	3,005,938,728	1,044,381,707	1,961,557,021	1,735,116,121
Total Manufacturing Cost	11,179,895,800	4,022,575,005	7,313,457,053	6,438,403,142
Work-in-Process (Closing)	(194,155,965)	(194,155,965)	(156,136,258)	(171,815,679)
Cost of Goods Manufactured	10,985,739,835	3,828,419,040	7,157,320,795	6,266,587,463
Finished Goods (Opening)	633,692,189	696,097,273	633,692,189	644,005,694
Finished Goods available	11,619,432,024	4,524,516,313	7,791,012,984	6,910,593,157
Cost of Physician Sample transferred to Sample Stock	(179,190,789)	(49,442,782)	(129,748,007)	(174,206,645)
Finished Goods (Closing)	(639,923,877)	(639,923,877)	(696,097,273)	(633,692,189)
	<u>10,800,317,358</u>	<u>3,835,149,654</u>	<u>6,965,167,704</u>	<u>6,102,694,323</u>

Item wise quantity and value of Finished Goods Stock are as follows :

Stock as January 01, 2015	Unit	Quantity	Value (Tk.)
Tablet, Capsule, Suppository & DPI	Million pcs.	426.64	389,211,055
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable and Inhaler	Million pcs.	6.78	236,895,019
Active Pharmaceutical Ingredients	Kg	2,450	7,586,115
			633,692,189
Stock as June 30, 2016			
Tablet, Capsule, Suppository & DPI	Million pcs.	370.24	351,741,050
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable and Inhaler	Million pcs.	6.85	257,318,388
Active Pharmaceutical Ingredients	Kg	7,029	18,650,439
Diet Care Products	Pcs	30,535	12,214,000
			639,923,877

25. Materials Consumed

This is made-up as follows :

	January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Opening Stock	1,062,093,352	1,374,684,313	1,062,093,352	1,228,275,639
Purchase	8,192,502,772	2,699,827,458	5,492,675,314	4,332,348,791
Closing Stock	(1,252,454,731)	(1,252,454,731)	(1,374,684,313)	(1,062,093,352)
	8,002,141,393	2,822,057,040	5,180,084,353	4,498,531,078

Amount in Taka

26. Factory Overhead

This consists of as follows :

Salary & Allowances	923,333,723	328,819,767	594,513,956	500,724,043
Repairs and Maintenance	247,729,698	87,928,385	159,801,313	104,500,367
Insurance Premium	22,309,704	9,166,206	13,143,498	12,514,466
Municipal Tax & Land Revenue	4,240,806	2,085,977	2,154,829	2,021,257
Advertisement	51,116	25,558	25,558	60,222
Registration & Renewal	18,495,348	6,208,730	12,286,618	10,631,435
Travelling & Conveyance	10,070,405	3,876,566	6,193,839	5,242,079
Entertainment	2,128,395	742,403	1,385,992	1,231,794
Research and Development	261,058,042	83,158,366	177,899,676	146,720,695
Printing & Stationery	23,889,555	7,742,008	16,147,547	13,914,877
Telephone, Internet & Postage	11,335,263	3,506,239	7,829,024	5,787,905
Toll Expense / (Income)	255,228,012	91,229,382	163,998,630	121,321,879
Electricity, Gas & Water	133,536,151	51,034,264	82,501,887	75,773,777
Training & Conference	8,900,920	1,072,225	7,828,695	5,046,880
Plant Certification and Regulatory Approvals	44,128,992	14,296,005	29,832,987	46,683,540
Depreciation	1,017,408,525	345,415,972	671,992,553	674,924,448
Other Expenses	22,094,073	8,073,654	14,020,419	8,016,457
	3,005,938,728	1,044,381,707	1,961,557,021	1,735,116,121

(a) Salary and allowances include an amount of Tk.17,859,896 being Company's Contribution to provident fund for the period January 2015 to June 2016.

(b) The value of imported stores and spares consumed during January 2015 to June 2016 Tk.138,743,197 is included in repairs & maintenance. This also includes maintenance of office, premises, vehicles, building, machinery, equipment and other infrastructures.

(c) Other expenses does not include any item exceeding 1% of total revenue.

27. Administrative Expenses

	Amount in Taka			
This consists of as follows :	January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Salary & Allowances	342,562,459	120,449,116	222,113,343	193,314,218
Rent	15,223,160	4,984,300	10,238,860	10,066,000
Repairs and Maintenance	55,605,625	18,551,667	37,053,958	30,338,920
Registration & Renewals	5,135,570	1,764,573	3,370,997	3,061,050
Travelling & Conveyance	34,405,438	11,831,723	22,573,715	19,583,051
Entertainment	7,288,932	2,377,334	4,911,598	4,063,944
Printing & Stationery	6,315,776	2,311,214	4,004,562	3,443,447
Audit Fee	2,100,000	700,000	1,400,000	1,300,000
Telephone, Internet & Postage	7,915,115	2,580,651	5,334,464	4,889,150
Electricity, Gas & Water	16,274,881	5,404,326	10,870,555	10,576,720
Legal & Consultancy	9,730,579	3,825,488	5,905,091	5,181,653
Company Secretarial, Regulatory- Fee and AGM Expense	53,230,398	14,036,401	39,193,997	39,532,229
Advertisement	180,296	107,606	72,690	58,138
Training & Conference	14,694,117	4,791,483	9,902,634	7,467,133
Depreciation	39,347,290	13,358,628	25,988,662	26,102,050
Remuneration to Independent Directors	580,000	260,000	320,000	140,000
Other Expenses	78,748,285	33,646,294	45,101,991	39,644,534
	689,337,921	240,980,804	448,357,117	398,762,237

(a) Salary and allowances include an amount of Tk. 8,489,904 being Company's Contribution to provident fund for the period January 2015 to June 2016.

(b) Repairs and maintenance includes maintenance of office, premises, vehicles, building, equipment and other infrastructures.

(c) Remuneration is paid to the Independent Directors for attending Board and Audit Committee Meetings.

28. Selling, Marketing and Distribution Expenses

This consists of as follows :				
Salary & Allowances	1,363,985,413	452,028,002	911,957,411	748,845,866
Rent	69,104,942	27,790,444	41,314,498	32,948,068
Repairs and Maintenance	9,477,978	2,899,223	6,578,755	5,719,886
Travelling & Conveyance	551,506,091	177,257,116	374,248,975	315,983,949
Entertainment	46,440,194	16,523,966	29,916,228	24,724,155
Printing & Stationery	48,418,106	17,825,606	30,592,500	27,433,905
Telephone, Internet & Postage	20,177,209	7,312,050	12,865,159	10,021,432
Electricity, Gas & Water	11,372,077	4,266,008	7,106,069	6,900,564
Market Research & New Products	57,798,871	21,599,701	36,199,170	31,046,918
Training & Conference	81,919,508	18,835,250	63,084,258	54,556,296
Insurance Premium	24,655,215	8,178,450	16,476,765	14,527,141
Sample Expense	258,105,667	92,822,945	165,282,722	150,637,854
Promotional Expenses	589,159,506	197,766,282	391,393,224	322,661,819
Literature/News Letter	179,138,483	69,074,607	110,063,876	93,314,746
Registration & Renewals	52,596,752	12,926,705	39,670,047	33,079,698
Export Insurance, Freight and C&F Expenses	63,647,883	18,050,363	45,597,520	38,333,120
Delivery Expense	543,786,599	203,307,856	340,478,743	296,368,010
Depreciation & Amortization	87,751,874	28,786,561	58,965,313	64,083,198
Other Expenses	27,551,642	8,639,297	18,912,345	16,065,656
	4,086,594,010	1,385,890,432	2,700,703,578	2,287,252,281

(a) Salary and allowances include an amount of Tk. 32,629,498 being Company's Contribution to provident fund for the period January 2015 to June 2016.

(b) Delivery expense includes distribution commission on local sales of Formulation and IV Fluid products paid to I & I Services Ltd., a "Related Party".

(c) Repairs and maintenance includes maintenance of office, premises, vehicles, building, equipment and other infrastructures.

(d) Sample expense includes VAT on sample and related despatch expense.

29. Other Income

Amount in Taka

This is arrived at as follows :

	January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
Interest on FDR & Short term Investment	404,847,333	100,525,928	304,321,405	489,970,647
Dividend Income	1,427,955	-	1,427,955	1,427,955
Royalty	10,634,016	-	10,634,016	24,763,177
Exchange Rate Fluctuation Gain / (Loss)	(5,406,570)	379,817	(5,786,387)	1,452,991
Profit on Sale of Fixed Assets (Note 35)	1,156,189	74,852	1,081,337	3,556,877
	412,658,923	100,980,597	311,678,326	521,171,647

30. Finance Cost

This is arrived at as follows :

Interest on Working Capital Loan	588,417,111	166,656,402	421,760,709	391,510,508
Interest on Project / Consortium Loan	152,835,514	35,067,043	117,768,471	175,227,715
Interest on Lease Finance	149,565,303	71,030,756	78,534,547	64,812,955
Interest on Loan from PF, WPPF & Welfare Fund	98,800,975	37,698,000	61,102,975	71,225,739
Other Bank Charges	40,563,498	10,759,966	29,803,532	21,538,046
	1,030,182,401	321,212,167	708,970,234	724,314,963

31. Contribution To WPPF & Welfare Funds

This represents statutory contribution by the company as per Bangladesh Labour Act (amendment) 2013. The amount is computed @ 5% of net profit before tax (but after charging such contribution).

32. Income Tax Expenses

This consists of as follows :

Amount in Taka

	January 2015- June 2016 (18 Months)	January- June 2016 (6 Months)	January - December 2015 (12 Months)	January - December 2014 (12 Months)
(a) Current Tax				
(i) Tax provision for current period	766,053,375	310,173,315	455,880,060	421,487,672
(ii) Short/(Excess) Provision for earlier year	(29,913,148)	-	(29,913,148)	15,295,172
	736,140,227	310,173,315	425,966,912	436,782,844
(b) Deferred Tax Expense / (Income)	(26,356,152)	16,765,213	(43,121,365)	144,475,316
	709,784,075	326,938,528	382,845,547	581,258,160

33. Earnings Per Share (EPS)

(a) Earnings attributable to the Ordinary Shareholders	Tk.	2,948,053,854	993,769,338	1,954,284,516	1,528,297,573
(b) Weighted average number of Ordinary Shares outstanding during the period (Note 3.15) Nos.		386,244,234	386,244,234	386,244,234	386,244,234
Earnings Per Share (EPS) / Adjusted EPS	Tk.	7.63	2.57	5.06	3.96

34. Related Party Disclosures

Following transactions were carried out with related parties in the normal course of business on arms length basis:

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at Period End
(a) I & I Services Ltd.	Local Delivery Distribution Commission	21,290,407,357 322,248,539	1,430,821,670 -
(b) Bangladesh Export Import Co. Ltd.	Short Term Investment & Interest there on	1,035,989,018	1,439,037,813

The Companies are subject to common control from same source.

35. Particulars of Disposal of Property, Plant and Equipment

The following assets were disposed off during the period ended 30 June 2016:

Particulars of Assets	Cost	Accumulated Depreciation	Written Down Value	Sales Price	Profit / (Loss)	Mode of Disposal	Name of Parties
Office Equipment	9,716,371	8,183,994	1,532,377	409,247	(1,123,130)	Negotiation	Various Individuals
Plant & Machinery	7,057,699	6,520,549	537,150	665,000	127,850	Negotiation	Various Individuals
Furniture & Fixture	16,946,545	11,988,652	4,957,893	4,929,870	(28,023)	Negotiation	Various Individuals
Transport & Vehicle	3,931,886	2,531,542	1,400,344	3,579,836	2,179,492	Negotiation	Various Individuals
Tk.	37,652,501	29,224,737	8,427,764	9,583,953	1,156,189		

36. Payment / Perquisites to Managers and Directors

(a) The aggregate amounts paid to/ provided for the Managers and above of the company is disclosed below :

	Amount in Taka
	January 2015- June 2016
	(18 Months)
Remuneration	295,224,430
Gratuity	10,779,325
Contribution to Provident Fund	12,831,690
Bonus	30,545,000
Medical	6,311,696
Others	32,899,347
	<u>388,591,488</u>

(b) The above includes salary, allowances, and perquisites amounting Tk. 47,917,879 paid to the Managing Director.

(c) This also includes Tk. 580,000 paid to Independent Directors for attending Board, Audit Committee and other meetings.

(d) Excepting as stated above (c) no board meeting fee was paid to any directors.

(e) No amount of money was expended by the company for compensating any member of the board for special services rendered.

37. Production Capacity and Utilization

Item	Unit	Production Capacity		Actual Production		Capacity Utilization	
		2015 (12 months)	2014 (12 months)	2015 (12 months)	2014 (12 months)	2015	2014
Tablet, Capsule, Suppository & DPI	Million Pcs	4,160.90	4,052.70	3,664.47	3,265.76	88.07%	80.58%
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable and Inhaler	Million Pcs	94.46	94.03	75.90	72.37	80.35%	76.96%

Production does not include goods manufactured under contract manufacturing arrangement from third party's' manufacturing sites.

38. Capital Expenditure Commitment

Company's committed capital expenditure relating to the procurement of Machinery and Equipment as on June 30, 2016 is US\$ 1,706,236.

39. Finance Lease Commitment

At 30 June 2016, the company has annual commitment under finance leases as set out below :

Leases expiring within 1 year	157,380,075
Leases expiring within 2-5 years (inclusive)	412,250,396
Tk.	<u>569,630,471</u>

40. Claim not Acknowledged as Debt

There is no claim against the company not acknowledged as debt as on 30 June 2016.

41. Un-availed Credit Facilities

The company has an un-availed foreign currency loan of US \$ 44.988 million sanctioned by BHF-Bank Aktiengesellschaft, Frankfurt, Germany to partially finance the machinery and equipment to be procured for expansion and diversification project being implemented by the company. The loan shall have to be availed latest by July 2017 as per approval of Bangladesh Investment Development Authority. However, the company has approached for extension of the same up to March 2018.

42. Payments Made in Foreign Currency :

	<u>Foreign Currency (Equivalent US\$)</u>	<u>Taka</u>
Import of Machinery, Equipments & Spares	15,775,833	1,243,943,838
Import of Raw & Packing Material	58,323,719	4,594,289,751
Regulatory Fees & Other Expenses	11,304,585	883,443,526

No other expenses including royalty, technical expert and professional advisory fee, interest, etc. was incurred or paid in foreign currencies except as stated above.

43. Foreign Exchange Earned / Received :

- (a) Collection from Export Sales of US\$ 16,200,450
- (b) Royalty US\$ 320,005
- (c) Loan from BHF Bank, Germany US\$ 6,571,052

44. Commission / Brokerage to selling agent :

No commission was incurred or paid to any sales agent nor any brokerage or discount other than conventional trade discount was incurred or paid against sales.

45. Contingent Liability

The company has a contingent liability aggregating Tk. 150,788,789 against disputed income tax claims for the year 1999, 2007, 2008 and 2010. The company has filed Income Tax Reference cases with the High Court Division of the supreme court against this claims.

There is also a disputed VAT claim aggregating Tk. 144,113,691 against the company. The Company own the verdict of the Appellate Tribunal in it's favour. The concerned authority filed appeal to the honorable High Court against this verdict. Additionally, there are claims of custom duty aggregating Tk. 22,507,358 against the indemnity bond issued by the company in connection with import of certain plant and machinery. The company has filed writ petitions against these claims.

If any liability arises on disposal of the cases, the company shall provide for such liability in the year of final disposal.

The company also has a contingent liability to the extent of Tk. 148,347,357 for third party corporate gurantee favoring Standard Bank Ltd. Dhanmondi Branch for Beximco Engineering Limited.

46. Events after The Reporting Period

On October 6, 2016 the Directors recommended 5% cash dividend (i.e. Tk. 0.5 per share) in addition to 10% cash dividend (i.e. Tk. 1.00 per share) and 5% Stock dividend (i.e. 5 shares for every 100 shares held) recommended on April 20, 2016.

Excepting above, no circumstances have arisen since the date of Statement of Financial Position which would require adjustment to, or disclosure in, the financial statements or notes thereto.

47. Financial Risk Management

The management of company has overall responsibility for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risks for its use of financial instruments.

Credit risk
Liquidity risk
Market risk

47.01 Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. As at 30 June 2016 substantial part of the receivables are those from its related company and subject to insignificant credit risk. Risk exposures from other financial assets. i.e. Cash at bank and other external receivables are nominal.

47.02 Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

47.03 Market Risk

Market risk is the risk that any change in market prices such as foreign exchange rates and interest will affect the company's income or the value of its holdings financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(a) Currency risk


The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw material, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad. The company have received foreign currency loan which shall be repaid in foreign currency.

(b) Interest rate risk


Interest rate risk is the risk that arises due to changes in interest rates on borrowing. The foreign currency loan is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rates. The company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Dhaka
6 October, 2016